Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C - Wikidata - awgldk - TriplyDB

Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C

Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C

http://www.wikidata.org/entity/Q34415178

about

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial.Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran.

P2860

Q36120739-3E0ABBBD-CE24-4970-994A-C6F9CEFD9501 Q37138784-CC03B12D-6589-4E3D-A1A3-DDB33BF34441

P2860

Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C

http://www.wikidata.org/entity/Q34415178

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Differential impact of adheren ...... iral titer chronic hepatitis C

@ast

Differential impact of adheren ...... iral titer chronic hepatitis C

@en

Differential impact of adheren ...... iral titer chronic hepatitis C

@nl

type

label

Differential impact of adheren ...... iral titer chronic hepatitis C

@ast

Differential impact of adheren ...... iral titer chronic hepatitis C

@en

Differential impact of adheren ...... iral titer chronic hepatitis C

@nl

prefLabel

Differential impact of adheren ...... iral titer chronic hepatitis C

@ast

Differential impact of adheren ...... iral titer chronic hepatitis C

@en

Differential impact of adheren ...... iral titer chronic hepatitis C

@nl

P1433

Q34415178-CCD236B7-9F4B-400F-B353-958A79B7DFF8

P1476

Q34415178-08359064-A201-4891-B64B-D8C08F4B82F9

P2093

Q34415178-17D0E074-E8DD-4BEB-BA52-C3949A3098C8

Q34415178-1A3EA5C8-756C-46B1-A26E-5E9DB337FDF9

Q34415178-20C4D9D7-A9C3-43E4-9705-86BB6E65DF1F

Q34415178-55D93C82-4E39-4F0E-B927-BE7C102FD8A5

Q34415178-5BC1F9E4-6471-41F1-B14B-E527BC491BA6

Q34415178-5D0A4C40-594B-4E7D-ACB7-7D226081B365

Q34415178-72722188-11AC-45A0-8E37-EC71B019D55A

Q34415178-87E28811-AF54-4629-B762-FB780B73AA77

Q34415178-8C9761F7-0B01-4BA9-95E0-0FD38537E837

Q34415178-93E2E69F-F12C-485E-A035-80CDF0420C9F

P2860

Q34415178-0B747019-4092-493E-B70D-1DED33FCF9F0

Q34415178-13251882-D030-4508-8A96-FB70B960725B

Q34415178-2B70A489-AFA6-425A-AEC9-C8AFB2A599C3

Q34415178-2E2B9B4B-4831-4ABD-8B5A-854DC69DB7C2

Q34415178-374EB8F4-AF59-4F84-9781-470DA3A0CFA1

Q34415178-3F44860B-09A3-445C-99A2-38CF7F7E35AF

Q34415178-4B35F832-9B2D-42E4-BCB6-85595CBE40ED

Q34415178-4CD71323-4904-42DA-AECC-09DB78CA8147

Q34415178-7A05FBBD-A1CA-4A14-BDFF-8B5EBF6A2C76

Q34415178-7C3AFA90-7804-4B32-92F6-4B21C1396945

P304

Q34415178-CDF56E2E-FE68-491C-948A-F3B07694DC37

P31

Q34415178-21056089-6637-43AB-9EC5-CB497FD491F5

P356

Q34415178-24CBFAEE-2448-416F-AC4C-D5733809B2C9

P478

Q34415178-7C30F5DF-E356-42DD-B40C-6F2AE5C086D0

P577

Q34415178-DB80B5B2-835E-4258-96BF-3097E88ECBAE

P5875

Q34415178-9E887981-DFD4-4228-9549-3F516A08BE35

P698

Q34415178-7EB364D0-AC52-4464-A609-394B6090443A

P921

Q34415178-D939DB5D-3757-4629-9299-96727C7C3184

P932

Q34415178-2591C6F0-736D-4B9C-B6C8-E5668FE25D81

P356

P1433

Hepatitis Research and Treatment

P1476

Differential impact of adheren ...... iral titer chronic hepatitis C

@en

P2093

Atsushi Nakano

http://www.w3.org/2001/XMLSchema#string

Hirokazu Shiozawa

http://www.w3.org/2001/XMLSchema#string

Jun-Ichiro Kamochi

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Atsukawa

http://www.w3.org/2001/XMLSchema#string

Koichi Shiraishi

http://www.w3.org/2001/XMLSchema#string

Makoto Numata

http://www.w3.org/2001/XMLSchema#string

Mitsuru Wasada

http://www.w3.org/2001/XMLSchema#string

Naruhiko Nagata

http://www.w3.org/2001/XMLSchema#string

Norihito Watanabe

http://www.w3.org/2001/XMLSchema#string

Sei-Ichiro Kojima

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: a multi-institution analysis.

P304

702748

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2010/702748

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49711658

http://www.w3.org/2001/XMLSchema#string

P698

21188199

http://www.w3.org/2001/XMLSchema#string

P921

P932

3003990

http://www.w3.org/2001/XMLSchema#string